Sipuleucel-T – the first FDA-approved immunotherapeutic drug based on autologous DCs treated with the recombinant prostatic acid phosphatase (PAP) and granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion, has shown not only no toxic effects, but also positive prospects in therapeutic approaches for the treatment of prostate cancer (6). This evidence concerns the gene ACP3 and prostate carcinoma.